FRI0165 RISK OF CKD IN MEMBRANOUS AND PROLIFERATIVE LUPUS NEPHRITIS - ANALYSIS OF A NATIONWIDE MULTICENTRE COHORT

Autor: Marco Flávio da Cunha, Filipa Farinha, A. R. Prata, M. J. Santos, R. Pinheiro Torres, Ruth J. Pepper, M. Couto, S. C. Barreira, Bruno Santos, Joana Rodrigues, C. Macieira, D. Fonseca, Luís Inês, Anisur Rahman, Mariana Luís, R. Freitas

Publikováno v: Annals of the Rheumatic Diseases. 79:666-667

Background:Lupus nephritis (LN) is one of the most severe manifestations of Systemic Lupus Erythematosus.Objectives:1) To compare proliferative (PLN), membranous (MLN) and mixed LN regarding clinical and laboratory presentation. 2) To investigate pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::030cc2bd444b1850d6a4c75d22d8b4bb
https://doi.org/10.1136/annrheumdis-2020-eular.3789

AB0747 MATERNAL AND FETAL OUTCOMES IN PREGNANT WOMEN WITH JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

Autor: Magali Pedro Costa, Agna Neto, M. H. Fernandes Lourenco, R. Pinheiro Torres, F. Pimentel Dos Santos, I Silva, H. Donato, Ana Filipa Mourão, Jaime Branco

Publikováno v: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP

Background:Juvenile idiopathic arthritis (JIA), one of the most common chronic diseases in children, can be classified in seven different categories according to its onset presentation. Concerns about pregnancy outcomes play a secondary role in disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca6f86ef00d99bac309dd40232f17209
https://doi.org/10.1136/annrheumdis-2021-eular.3647

AB0014 METHOTREXATE - IMPLICATIONS OF PHARMACOGENETICS IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

Autor: R. Pinheiro Torres, Jaime Branco, F. Pimentel Dos Santos

Publikováno v: Annals of the Rheumatic Diseases. 80:1041.2-1042

Background:Methotrexate (MTX) is an anti-folate drug with anti-proliferative and anti-inflammatory effects. MTX proved to be the most highly effective, fast-acting disease modifying anti-rheumatic drug (DMARD), being widely used for the treatment of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea90a106259960cb44454e4227188aa2
https://doi.org/10.1136/annrheumdis-2021-eular.3749

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Muscle dysfunction in axial spondylarthritis: the MyoSpA study.

Autor: Neto A; Rheumatology Department, Hospital Central do Funchal, Madeira; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal. agnaneto@gmail.com., Pinheiro Torres R; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon,and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Ramiro S; Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, and Rheumatology Department, Leiden University Medical Center, Leiden, and Zuyderland Medical Center, Heerlen, The Netherlands., Sardoo A; Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Rodrigues-Manica S; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon,and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Lagoas-Gomes J; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon,and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Domingues L; Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Lage Crespo C; Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Teixeira D; Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Sepriano A; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon,and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Masi AT; Department of Medicine, University of Illinois College of Medicine, Peoria, IL, USA., Nair K; Department of Mechanical Engineering, Bradley University, Peoria, IL, USA., Gomes-Alves P; Instituto de Biologia Experimental e Tecnológica (IBET), Oeiras, Portugal., Costa J; Laboratory of Glycobiology, Instituto de Tecnologia Química e Biológica (ITQB) António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal., Branco JC; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon,and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal., Pimentel-Santos FM; Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon,and Chronic Diseases Research Center (CEDOC), NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.

Publikováno v: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2022 Feb; Vol. 40 (2), pp. 267-273. Date of Electronic Publication: 2021 Nov 23.